-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-508475-36-00
5
2024-10-29
Atherosclerotic Cardiovascular Disease
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-503394-37-00
5
2024-10-23
Acute Myeloid Leucaemia
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508817-18-00
5
2024-10-08
Perennial Allergic Rhinitis (PAR)
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-509775-16-00
4
2024-10-03
Ulcerative colitis
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2024-511688-27-00
4
2024-09-19
Myelofibrosis
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-508520-36-00
5
2024-09-06
Seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
-
2023-506704-14-00
4
2024-09-04
Moderately to Severely Active Crohn's Disease
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-506503-26-00
5
2024-07-31
Polyneuropathy, Inflammatory Demyelinating, Chronic
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2024-511309-47-00
4
2024-07-17
moderate thrombocytopenia
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-507407-59-00
5
2024-07-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-501697-19-01
5
2024-06-18
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke